<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599284</url>
  </required_header>
  <id_info>
    <org_study_id>VCP1-Ⅱ-01</org_study_id>
    <nct_id>NCT03599284</nct_id>
  </id_info>
  <brief_title>The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel</brief_title>
  <official_title>The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-controlled, Dose-exploration Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu vcare pharmaceutical technology co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu vcare pharmaceutical technology co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled,&#xD;
      dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and&#xD;
      planned percutaneous coronary intervention （PCI） will be randomized after informed consent,&#xD;
      in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg&#xD;
      loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading&#xD;
      followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by&#xD;
      7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28&#xD;
      days. The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel&#xD;
      antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease&#xD;
      during and after PCI compared with clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">July 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>Inhibition of platelet aggregation will be assessed by Verifynow System</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Platelet Aggregation Inhibitors</condition>
  <arm_group>
    <arm_group_label>Experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicagrel 5mg</intervention_name>
    <description>Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days</description>
    <arm_group_label>Experimental group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicagrel 6mg</intervention_name>
    <description>Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days</description>
    <arm_group_label>Experimental group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicagrel 7.5mg</intervention_name>
    <description>Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days</description>
    <arm_group_label>Experimental group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <description>Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female aged 18-75.&#xD;
&#xD;
          -  Weight ≥ 50 kg&#xD;
&#xD;
          -  Patients with coronary atherosclerotic heart disease diagnosed clinically and planned&#xD;
             percutaneous coronary intervention&#xD;
&#xD;
          -  Patients with ability and willingness to sign informed consent and adherence to trial&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemorrhagic symptoms (such as hematemesis, melena, severe or recurrent epistaxis,&#xD;
             hemoptysis, marked hematuria, gastrointestinal bleeding, or intracranial hemorrhage),&#xD;
             or suspected vascular malformations (such as aneurysms), or abnormal bleeding history&#xD;
             (such as abnormal hemorrhage attributed to tooth extraction), himself or his immediate&#xD;
             family with coagulation or bleeding disorders (such as hemophilia);&#xD;
&#xD;
          -  Non-ST-segment elevation acute coronary syndrome (&lt;2h emergency PCI), or ST-segment&#xD;
             elevation myocardial infarction within 7 days;&#xD;
&#xD;
          -  Patients with suspected aortic dissection;&#xD;
&#xD;
          -  Patients with negative coronary Computed Tomography angiography（CTA）(coronary CTA&#xD;
             depending on investigator);&#xD;
&#xD;
          -  Patients with severe disease and life expectancy &lt;1 year;&#xD;
&#xD;
          -  Patients with acute peptic ulcer;&#xD;
&#xD;
          -  History of hemorrhagic stroke or history of ischemic stroke within 6 months before&#xD;
             screening and a definite diagnosis of structural abnormalities in the central nervous&#xD;
             system;&#xD;
&#xD;
          -  Patients with uncontrolled high blood pressure (systolic blood pressure ≥ 180 mmHg or&#xD;
             diastolic blood pressure ≥ 110 mmHg) after drug treatment during screening;&#xD;
&#xD;
          -  One of the following conditions: cardiogenic shock, chronic congestive heart with&#xD;
             failure New York Heart Association (NYHA) grade ≥ III grade or left ventricular&#xD;
             ejection fraction determined by echocardiography &lt; 35%, hypotension (systolic pressure&#xD;
             &lt; 90 mmHg and or diastolic pressure &lt; 60 mmHg), severe arrhythmias (including&#xD;
             high-degree atrioventricular block, sick sinus syndrome, persistent ventricular&#xD;
             tachycardia), severe pulmonary insufficiency, pulmonary embolism, and hepatic&#xD;
             insufficiency (ALT or AST caused by non-cardiac diseases exceeding the upper limit of&#xD;
             normal by more than 3 times), severe renal insufficiency (eGFR &lt; 30 ml/min),&#xD;
             cirrhosis;&#xD;
&#xD;
          -  Patients Received P2Y12 receptor antagonist and Ⅱb/IIIa receptor inhibitor, oral&#xD;
             anticoagulant (warfarin, rivaroxaban, dabigatran, etc.) within 14 days before&#xD;
             screening;&#xD;
&#xD;
          -  Prolonged cardiopulmonary resuscitation (more than 10 minutes) or severe trauma within&#xD;
             2 weeks before screening;&#xD;
&#xD;
          -  Patients plan to undergo another surgery within 1 month after participating in this&#xD;
             trial，or plan to undergo PCI procedure performed several times during the test (except&#xD;
             for the end of the safety follow-up);&#xD;
&#xD;
          -  History of severe allergies, non-allergic drug reactions or allergies to 2 or more&#xD;
             drugs (including contrast agents), or known allergies to the similar drugs&#xD;
             (clopidogrel, ticagrelor) as the study drug or contraindication of aspirin;&#xD;
&#xD;
          -  Patients with mental disorders or alcohol dependence;&#xD;
&#xD;
          -  Patients being receiving any experimental medicine or experimental medical devices;&#xD;
&#xD;
          -  Prothrombin time (PT)&gt; 1.3 times the upper limit of normal or international normalized&#xD;
             ratio (INR)&gt; 2.0;&#xD;
&#xD;
          -  Platelet count (PLT) &lt; 100×10^9/L or &gt; 600×10^9/L;&#xD;
&#xD;
          -  Hemoglobin &lt; 10g/dL;&#xD;
&#xD;
          -  Patients who cannot tolerate dual antiplatelet therapy for 28 days;&#xD;
&#xD;
          -  Female of reproductive age with positive blood pregnancy test;&#xD;
&#xD;
          -  Female with gestational intention or in lactation;&#xD;
&#xD;
          -  Other unsuitable conditions considered by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical Universily</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhongshan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital of Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jinin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the General Hospital of Shenyang Military Region of The Chinese People's Liberation Army（The General Hospital of Shenyang Military）</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110134</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qinghai Provincial People's Hospital</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <zip>810007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuncheng Central Hospital</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <zip>044000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <zip>646000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjing</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

